Title : A Pharmacogenetic Approach to the Treatment of Patients With PPARG Mutations.

Pub. Date : 2018 Jun

PMID : 29622583






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Furthermore, in testing novel mutations with both prototypic endogenous (e.g., prostaglandin J2 [PGJ2]) and synthetic ligands (thiazolidinediones, tyrosine agonists), we observed that synthetic agonists selectively rescue function of some peroxisome proliferator-activated receptor-gamma (PPARgamma) mutants. 9-deoxy-delta-9-prostaglandin D2 peroxisome proliferator activated receptor gamma Homo sapiens
2 Furthermore, in testing novel mutations with both prototypic endogenous (e.g., prostaglandin J2 [PGJ2]) and synthetic ligands (thiazolidinediones, tyrosine agonists), we observed that synthetic agonists selectively rescue function of some peroxisome proliferator-activated receptor-gamma (PPARgamma) mutants. 9-deoxy-delta-9-prostaglandin D2 peroxisome proliferator activated receptor gamma Homo sapiens
3 Both PPARgamma mutants exhibit negligible constitutive or PGJ2-induced transcriptional activity but respond readily to synthetic agonists in vitro, with structural modeling providing a basis for such differential ligand-dependent responsiveness. 9-deoxy-delta-9-prostaglandin D2 peroxisome proliferator activated receptor gamma Homo sapiens